Montelukast Almus (Montelukast Sodium)

Montelukast, the active ingredient in Montelukast Almus, is a leukotriene receptor antagonist presented as an oral tablet for systemic use. It is employed to manage chronic asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in adult and pediatric patients through daily maintenance therapy.

GNH USA supplies Montelukast Almus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide with a focus on quality assurance, regulatory compliance, and reliable global logistics. Our distribution network ensures timely delivery to diverse healthcare settings, adhering to stringent storage and handling standards, and we collaborate with certified manufacturers to maintain product integrity and support clinical needs across multiple regions through transparent communication, comprehensive documentation, and responsive customer service for all procurement inquiries through experience.

Montelukast acts on the leukotriene pathway to provide long‑term control of several respiratory conditions.

Asthma: Improves daily symptom control, reduces the frequency and severity of exacerbations, and may decrease the need for rescue inhaler use in patients requiring maintenance therapy. Allergic rhinitis: Alleviates nasal congestion, sneezing, itching and watery discharge associated with seasonal or perennial allergic rhinitis, improving overall quality of life. Exercise‑induced bronchoconstriction: Prevents airway narrowing triggered by physical activity, allowing better exercise tolerance and reducing post‑exercise respiratory symptoms.

Montelukast is generally well tolerated, but a range of adverse reactions have been reported.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: intermittent discomfort. - Cough: non‑productive. - Nausea: occasional. - Dyspepsia: indigestion or upset stomach. - Fatigue: feeling of tiredness. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips or airway. - Stevens‑Johnson syndrome: severe skin rash with blistering. - Eosinophilic granulomatosis with polyangiitis: systemic vasculitis with eosinophilia. - Suicidal thoughts or behavior: mood changes requiring immediate medical attention. - Hepatic injury: elevated liver enzymes or hepatitis. - Anaphylaxis: severe allergic reaction with hives and breathing difficulty.

When prescribing Montelukast, several precautions should be considered.

Assess asthma control: evaluate frequency of symptoms before initiating therapy. Monitor neuropsychiatric events: watch for mood changes, depression or suicidal thoughts. Use caution in hepatic impairment: adjust therapy if liver disease is present. Review concomitant medications: consider potential interactions with CYP inducers. Avoid in patients with known hypersensitivity to montelukast or any tablet components. Store at room temperature: keep in the original packaging, protect from moisture and heat.

Montelukast may interact with other medicines; awareness of these interactions helps maintain safety and efficacy.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin) can markedly lower montelukast plasma concentrations, potentially reducing therapeutic effect. - Phenobarbital, a hepatic enzyme inducer, decreases montelukast levels and may necessitate clinical monitoring. - Co‑administration with other leukotriene antagonists (e.g., zafirlukast) offers no additive benefit and raises the risk of overlapping adverse reactions.

Moderate Interactions (Monitor Closely): - Antidepressants such as SSRIs or SNRIs may increase the likelihood of neuropsychiatric events when combined with montelukast; patients should be observed for mood changes. - Antihistamines, particularly when used with CNS depressants, can enhance sedation; dosage adjustments may be required. - Theophylline metabolism may be altered; clinicians should monitor theophylline serum concentrations during combined therapy.